TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX),, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...
Impact of Liposomal Bupivacaine on Healthcare Resource Utilization and Costs in Patients Undergoing Total Knee Arthroplasty ...
Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
Opioids were once the go-to solution for surgical pain relief, but unwanted side effects like nausea, dizziness, constipation ...
Please provide your email address to receive an email when new articles are posted on . Results showed the addition of a single-injection proximal sciatic nerve block to an adductor canal block ...
— New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures — An adductor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback